Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04296890
Title A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors ImmunoGen, Inc.

ovarian serous carcinoma

fallopian tube cancer

peritoneum cancer


Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL

No variant requirements are available.